Stoke Therapeutics (NASDAQ:STOK) Trading 9.1% Higher

Stoke Therapeutics, Inc. (NASDAQ:STOK)’s share price was up 9.1% on Monday . The stock traded as high as $14.82 and last traded at $14.81. Approximately 357,091 shares traded hands during mid-day trading, a decline of 60% from the average daily volume of 890,398 shares. The stock had previously closed at $13.58.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Stoke Therapeutics in a research note on Thursday, April 4th. HC Wainwright restated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a research report on Tuesday, May 7th. JPMorgan Chase & Co. boosted their price objective on Stoke Therapeutics from $6.00 to $13.00 and gave the company a “neutral” rating in a research report on Tuesday, March 26th. TD Cowen raised Stoke Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 26th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Friday, June 28th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $20.57.

Stoke Therapeutics Price Performance

The stock’s 50 day moving average is $14.38 and its 200-day moving average is $10.32. The company has a market capitalization of $789.62 million, a P/E ratio of -6.11 and a beta of 0.87.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Monday, May 6th. The company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.03. The firm had revenue of $4.22 million for the quarter, compared to analysts’ expectations of $3.33 million. On average, equities research analysts anticipate that Stoke Therapeutics, Inc. will post -2.3 EPS for the current year.

Insiders Place Their Bets

In related news, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $13.75, for a total transaction of $137,500.00. Following the completion of the transaction, the insider now directly owns 2,485 shares of the company’s stock, valued at approximately $34,168.75. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 11.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC boosted its stake in Stoke Therapeutics by 53.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock worth $40,000 after purchasing an additional 1,038 shares in the last quarter. Assenagon Asset Management S.A. bought a new position in shares of Stoke Therapeutics in the second quarter worth approximately $19,835,000. SG Americas Securities LLC grew its holdings in shares of Stoke Therapeutics by 610.3% during the second quarter. SG Americas Securities LLC now owns 68,601 shares of the company’s stock valued at $927,000 after buying an additional 58,943 shares during the last quarter. Lynx1 Capital Management LP increased its position in shares of Stoke Therapeutics by 25.0% during the first quarter. Lynx1 Capital Management LP now owns 3,696,820 shares of the company’s stock valued at $49,907,000 after acquiring an additional 739,902 shares in the last quarter. Finally, Artal Group S.A. bought a new stake in shares of Stoke Therapeutics during the first quarter valued at approximately $4,050,000.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.